Ganirelix acetate injection is used for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
Sucralfate Oral Suspension had a market value of $188.5 million, of which $157.9 million represents generic sales, for the 12 months ending December 2021, according to IQVIA.
